During the past decade, Gastroenterology Group of Naples conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 31 clinical trials were completed, i.e. on average, 66% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 20 clinical trials were completed. i.e. 105.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gastroenterology Group of Naples" #1 sponsor was "Pfizer" with 8 trials, followed by "Shire" with 5 trials sponsored, "Takeda" with 5 trials sponsored, "Celgene" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gastroenterology Group of Naples" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Sucampo Pharmaceuticals, Inc." with 2 trials as a collaborator, "Syneos Health" with 2 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Gastroenterology Group of Naples" are "Crohn's Disease" (16 trials), "Ulcerative Colitis" (16 trials), "Colitis, Ulcerative" (6 trials), "Crohn Disease" (5 trials) and "Gastroparesis" (3 trials). Many other conditions were trialed in "Gastroenterology Group of Naples" in a lesser frequency.

Most popular intervention types in "Gastroenterology Group of Naples" are "Drug" (52 trials), "Other" (9 trials), "Biological" (7 trials), "Diagnostic Test" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "Etrasimod" (5 trials), "Filgotinib" (5 trials), "GED-0301" (4 trials) and "Guselkumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Gastroenterology Group of Naples" are 60 trials for "All" genders.

Currently, there are NaN active trials in "Gastroenterology Group of Naples". undefined are not yet recruiting, 13 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Gastroenterology Group of Naples, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Gastroenterology Group of Naples, 2 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".